Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 1,622 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Disorder Clear all

Conditions: Retinal Vein Occlusion
Interventions: Ranibizumab 0.5mg (monthly), Ranibizumab 2.0mg (monthly), Pro re nata (prn) ranibizumab, Pro re nata (prn) Laser photocoagulation; Drug · Procedure
Lead sponsor: Peter A Campochiaro, MD; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Macular Degeneration
Interventions: Ranibizumab; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 50 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Age-related Macular Degeneration, Depression
Interventions: BA-LVR, ST-LVR; Behavioral
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 65 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Biological
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more

Conditions: Retinal Disease, Glaucoma
Interventions: P200TE, Spectral OCT/SLO; Device
Lead sponsor: Optos, PLC; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2016
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Retinopathy
Interventions: Not listed
Lead sponsor: Julia Haller; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Retinal Neovascularization
Interventions: Not listed
Lead sponsor: Notal Vision Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • St Louis, Missouri • Florence, South Carolina

Conditions: Diabetic Macular Edema (DME), Diabetic Retinopathy
Interventions: Intravitreal dexamethasone implant; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetic Retinopathy
Interventions: triamcinolone acetonide (Kenalog); Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
Interventions: ranibizumab (Lucentis); Drug
Lead sponsor: Retina Associates of Cleveland, Inc; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Choroidal Neovascularization, Age-Related Maculopathy
Interventions: dexamethasone, ranibizumab, sham; Drug · Biological · Other
Lead sponsor: Allergan; Industry
Eligibility: 50 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boynton Beach, Florida

Conditions: Retinitis Pigmentosa
Interventions: Vitamin A; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Disease, Healthy
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sepsis, Bronchopulmonary Dysplasia, Necrotizing Enterocolitis, Retinopathy of Prematurity, Systemic Inflammatory Response Syndrome
Interventions: Parenteral cysteine-HCl supplementation, Placebo - added premasol; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: Up to 30 Days
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions: Nicotinamide, Standard Glaucoma Therapy; Drug · Other
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 80 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Age-related Macular Degeneration
Interventions: Omega-3 fatty acids (fish oil), Vitamin D3, Vitamin D3 placebo, Fish oil placebo; Drug · Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 50 Years and older
Enrollment: 25,871 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Interventions: i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham; Device
Lead sponsor: i-Lumen Scientific, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 10
States / cities: Phoenix, Arizona • Walnut Creek, California • Lemont, Illinois + 7 more

Conditions: Retinoblastoma, Melanoma, Sarcoma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 7 Years and older
Enrollment: 2,136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2024
U.S. locations: 4
States / cities: Bethesda, Maryland • Boston, Massachusetts • New York, New York + 1 more

Conditions: Diabetic Retinopathy
Interventions: ARDA software application; Diagnostic Test
Lead sponsor: Verily Life Sciences LLC; Industry
Eligibility: 22 Years and older
Enrollment: 1,012 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Glendale, Arizona • Jonesboro, Arkansas • Montclair, California + 10 more

Conditions: Diabetic Retinopathy
Interventions: Sirolimus; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Age Related Macular Degeneration
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Foscarnet sodium; Drug
Lead sponsor: Astra USA; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stargardt's Macular Dystrophy
Interventions: MA09-hRPE; Biological
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Retinitis Pigmentosa
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions

A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD

Low Vision Depression Prevention Trial for Age Related Macular Degeneration

ADVM-022 Intravitreal Gene Therapy for Wet AMD

Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes

Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart

Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD

Corticosteroid for Diabetic Macular Edema (DME) Study

Vascular Remodeling and the Effects of Angiogenic Inhibition in Diabetic Retinopathy

Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

Optical Coherence Tomography Comparative Study

Cysteine Supplementation in Critically Ill Neonates

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

Retinoblastoma Biomarker Study

ARDA Software for the Detection of mtmDR

Sirolimus to Treat Diabetic Macular Edema

Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

Study of Usher Syndromes, Type 1 and Type 2